H.R. 2197: No 340B Savings for Transgender Care Act (119th Congress) Bill Summary

This bill, titled the "No 340B Savings for Transgender Care Act," seeks to prohibit specific uses of funds associated with the 340B drug pricing program. The main provisions of the bill are as follows:

Purpose of the Bill

The bill aims to prevent covered entities that participate in the 340B program from using savings gained through the program for certain medical services for transgender individuals.

340B Drug Pricing Program Overview

The 340B program allows healthcare organizations, known as covered entities, to purchase outpatient drugs at reduced prices. The savings from this program are generally intended to help these entities provide care to underserved populations.

Prohibitions Set by the Bill

The bill specifically states that these covered entities cannot use the savings from the 340B drug pricing program to fund:

Sex reassignment surgeries intended for the gender alteration of transgender individuals.
Hormone treatments meant for the gender alteration of transgender individuals.

Definition of Key Terms

Within the context of the bill, two key terms are defined:

Covered Entity: This term refers to organizations that are recognized as participating in the 340B program, which may include hospitals, health clinics, and other healthcare providers that serve low-income or uninsured patients.
Services Described: This refers specifically to the medical procedures and treatments mentioned above, which the bill seeks to regulate in terms of financing through 340B savings.

Legislative Process

The bill was introduced in the House of Representatives and has been referred to the Committee on Energy and Commerce for consideration.

Impact of the Bill

The legislation sets forth clear restrictions on how savings from the 340B program can be allocated, thereby impacting financial decision-making for covered entities regarding transgender healthcare services. The intent is to ensure that the resources saved through this program are not directed toward these specific treatments.